Supplementary Material for ONS Guidelines™ Management of Opioid-Induced and Treatment-Related Constipation: Systematic Review and Meta-Analysis

Table of Contents

1. PICO questions
2. Search strategies
3. Evidence risk of bias figure
4. Evidence Profiles

• Bowel regimen and lifestyle education vs. lifestyle education for opioid-induced constipation
• Osmotic PEG and lifestyle education vs. lifestyle education for opioid-induced constipation
• Methylnaltrexone (subcutaneous or oral) and bowel regimen vs. bowel regimen for opioid-induced constipation
• Naldemedine (0.2 mg) and bowel regimen vs. bowel regimen for opioid-induced constipation
• Naloxegol and bowel regimen vs. bowel regimen for opioid-induced constipation
• Lubiprostone and bowel regimen vs. bowel regimen for opioid-induced constipation
• Linaclotide and bowel regimen vs. bowel regimen for opioid-induced constipation
• Prucalopride and bowel regimen vs. bowel regimen for opioid-induced constipation
• Osmotic or stimulant laxatives and lifestyle education vs. lifestyle education for non-opioid-related constipation
• Acupuncture and lifestyle education vs. lifestyle education for non-opioid-related constipation
• Electroacupuncture and lifestyle education vs. lifestyle education for non-opioid-related constipation

5. Forest plots

• Laxatives—Bowel movement frequency
• Laxatives—Adverse events leading to treatment discontinuation
• Naldemedine—Spontaneous Bowel Movements (SBMs)
• Naldemedine—Adverse events leading to treatment discontinuation
• Acupuncture—Bristol Stool Form Scale
• Acupuncture—Adverse events
• Acupuncture—Development of constipation

6. Characteristics of included studies